# US 2022/0362297 A1 · Intracellular genomic transplant and methods of therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0362297 A1
- Document ID: US20220362297A1
- Status: Published application
- Kind: A1
- Application number: 17/674,378
- Filed: 2022-02-17
- Published: 2022-11-17
- Earliest claimed: 2015-07-31
- Assignees: Regents of the University of Minnesota; Intima Bioscience, Inc.; The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Applicants: Regents of the University of Minnesota; Intima Bioscience, Inc.; The U.S.A., as Represented by the Secretary, Department of Health and Human Services
- Inventors: Branden MORIARITY; Beau WEBBER; Modasir CHOUDHRY; Steven A. ROSENBERG; Douglas C. PALMER; Nicholas P. RESTIFO
- Web page: https://patentgrep.com/patent/US20220362297A1

## CPC

- C07K 14/4718: {Cytokine-induced proteins}
- C12N 5/0636: {T lymphocytes}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 14/7158: {for chemokines}
- C12N 5/0662: {Stem cells}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.

## Claims

### Claim at position 1

-150. (canceled)

### Claim 151

A pharmaceutical composition comprising:
(a) population of genetically modified immune cells comprising:
(i) a genomic disruption in a cytokine inducible SH2-containing protein (CISH) gene target sequence; and
(ii) an exogenous chimeric antigen receptor (CAR) or an exogenous T-cell receptor (TCR), wherein the exogenous CAR or the exogenous TCR target a tumor cell antigen, wherein the tumor cell antigen is a MUC-1 antigen or a CD70 antigen,
wherein the population of genetically modified immune cells comprise a population of T cells, a population of NK cells, or a combination thereof, and
(b) a pharmaceutically acceptable carrier or excipient.

### Claim 152 (depends on 151)

The pharmaceutical composition of claim 151, wherein the exogenous CAR or the exogenous TCR are encoded by an exogenous nucleic acid, wherein the exogenous nucleic acid is inserted into an endogenous TCR gene.

### Claim 153 (depends on 151)

The pharmaceutical composition of claim 151, wherein the exogenous CAR or the exogenous TCR are encoded by an exogenous nucleic acid, wherein the exogenous nucleic acid is inserted adjacent to, near, or within the CISH target sequence.

### Claim 154 (depends on 151)

The pharmaceutical composition of claim 151, wherein the genomic disruption is an endonuclease-mediated indel within 5 base pairs of a protospacer adjacent motif (PAM) sequence and a disruption efficiency of at least 30%

### Claim 155 (depends on 151)

The pharmaceutical composition of claim 151, wherein the genetically engineered population of immune cells are cluster of differentiation 56 positive (CD56*) cells.

### Claim 156 (depends on 151)

The pharmaceutical composition of claim 151, wherein the population of genetically modified immune cells comprise a population of autologous cells derived from a human subject in need of treatment with the pharmaceutical composition.

### Claim 157 (depends on 151)

The pharmaceutical composition of claim 151, wherein the population of genetically modified immune cells comprise a population of immune cells derived from pluripotent stem cells.

### Claim 158 (depends on 154)

The pharmaceutical composition of claim 154, wherein the disruption efficiency of the CISH gene target sequence is determined by tracking of indels by decomposition (TIDE) analysis.

### Claim 159

A pharmaceutical compositions comprising:
(a) population of genetically modified natural killer (NK) cells comprising:
a genomic disruption in a cytokine inducible SH2-containing protein (CISH) gene target sequence and at least one additional genomic disruption in a transforming growth factor beta receptor II (TGFBRII) gene target sequence; and
(b) a pharmaceutically acceptable carrier or excipient.

### Claim 160 (depends on 159)

The pharmaceutical composition of claim 159, wherein the genetically engineered population of NK cells are CD56+ cells.

### Claim 161 (depends on 159)

The pharmaceutical composition of claim 159, wherein the population of genetically modified NK cells further comprise an exogenous CAR or an exogenous TCR, wherein the exogenous CAR or the exogenous TCR target a tumor antigen.

### Claim 162 (depends on 161)

The pharmaceutical composition of claim 161, wherein the exogenous CAR or the exogenous TCR are encoded by an exogenous nucleic acid.

### Claim 163 (depends on 161)

The pharmaceutical composition of claim 161, wherein the exogenous CAR or the exogenous TCR are encoded by an exogenous nucleic acid, wherein the exogenous nucleic acid is inserted adjacent to, near, or within the CISH target sequence or the TGFBRII target sequence.

### Claim 164 (depends on 159)

The pharmaceutical composition of claim 159, wherein the population of genetically modified NK cells comprise a population of autologous cells derived from a human subject in need of treatment with the pharmaceutical composition.

### Claim 165 (depends on 159)

The pharmaceutical composition of claim 159, wherein the population of genetically modified NK cells comprise a population of NK cells derived from pluripotent stem cells.

### Claim 166 (depends on 159)

The pharmaceutical composition of claim 159, wherein at least one genomic disruption is an endonuclease-mediated indel within 5 base pairs of a protospacer adjacent motif (PAM) sequence and a disruption efficiency of at least 30%.

### Claim 167 (depends on 159)

The pharmaceutical composition of claim 159, wherein the disruption efficiency of at least one gene target sequence is determined by tracking of indels by decomposition (TIDE) analysis.
